What Is a PSUR/PBRER? Purpose and Regulatory Expectations – pharmacovigilance consulting What Is a PSUR/PBRER? Purpose and Regulatory Expectations Periodic Safety Update Reports (PSUR) and Periodic Benefit-Risk Evaluation Reports (PBRER) serve as crucial documents within the realms of pharmacovigilance and regulatory compliance. This article elucidates the purpose, structure, and regulatory expectations surrounding these reports, aimed specifically at professionals involved in pharmacovigilance consulting, biopharmaceutical regulatory affairs, and related fields. How to Understand the Purpose of PSURs and PBRERs The primary purpose of both PSURs and PBRERs lies in tracking and evaluating the safety profile of medicinal products once they are marketed….

PSUR vs. PBRER: Key Differences Explained – pharmacovigilance research PSUR vs. PBRER: Key Differences Explained Periodic Safety Update Reports (PSURs) and Periodic Benefit-Risk Evaluation Reports (PBRERs) are essential components of pharmacovigilance research, aimed at ensuring drug safety throughout the lifecycle of medicinal products. Both reports serve critical functions within the realms of biopharmaceutical regulatory affairs and must be accurately formulated to comply with international regulations. This article provides a comprehensive guide on the key differences between PSUR and PBRER, including their structures, data expectations, and common reviewer focus points, ensuring that professionals achieve the highest standards in pharmacovigilance research. How…

EU PSUR Submission via the PSUR Repository: A Step-by-Step Guide – biopharmaceutical regulatory affairs EU PSUR Submission via the PSUR Repository: A Step-by-Step Guide Periodic Safety Update Reports (PSURs) play a critical role in ensuring the safe use of medicinal products and in the communication of ongoing drug safety information to regulatory authorities. For those involved in biopharmaceutical regulatory affairs, understanding the submission process via the PSUR Repository is essential. This guide provides a detailed framework on how to effectively navigate this process. How to Understand the PSUR Submission Requirements Before submitting a PSUR via the PSUR Repository, it is…

ICH E2C(R2) Guidelines: Structuring a Compliant PBRER – pharmacy compliance consulting ICH E2C(R2) Guidelines: Structuring a Compliant PBRER The International Council for Harmonisation (ICH) E2C(R2) guidelines serve as a crucial framework for pharmaceutical companies tasked with the preparation of Periodic Benefit-Risk Evaluation Reports (PBRERs). This detailed how-to manual outlines the essential components required for structuring a compliant PBRER, ensuring adherence to global regulations in drug safety reporting. How to Understand the ICH E2C(R2) Guidelines for PBRERs Before diving into the components needed for a compliant PBRER, it is vital to fully understand the ICH E2C(R2) guidelines. These guidelines are designed…

Timelines and Frequencies for PSUR Submission Across Regions – master’s in regulatory affairs and quality assurance Timelines and Frequencies for PSUR Submission Across Regions Periodic Safety Update Reports (PSURs) are essential components of pharmacovigilance designed to provide scientific evaluation of the safety profile of a drug over time. As a regulatory professional in the life sciences sector, understanding the timelines and frequencies for PSUR submission is pivotal. This article outlines critical steps and considerations necessary for ensuring compliance across various regions such as the US, EU, and India, catering specifically to those pursuing a master’s in regulatory affairs and quality…

FDA Periodic Safety Reporting Requirements for NDA Holders – life science compliance consulting FDA Periodic Safety Reporting Requirements for NDA Holders In the field of life science compliance consulting, understanding the framework of periodic safety reporting is essential for ensuring compliance with FDA regulations. This article provides a comprehensive guide on the periodic safety reporting requirements for New Drug Application (NDA) holders. It details the expectations set forth by the FDA, the structure of safety reports, and effective methods for maintaining compliance. This guidance is crucial for regulatory affairs professionals working within the pharmaceutical industry, particularly those focusing on pharmacovigilance…

PSUR Requirements for Generics and Biosimilars – regulatory affairs in pharmaceutical industry PSUR Requirements for Generics and Biosimilars: A How-To Guide for Regulatory Affairs in the Pharmaceutical Industry The role of regulatory affairs in the pharmaceutical industry is critical for ensuring that generics and biosimilars adhere to safety, efficacy, and quality standards. One fundamental aspect of this regulatory landscape is the Periodic Safety Update Report (PSUR). This article provides a comprehensive guide on the PSUR requirements specifically tailored for generics and biosimilars, emphasizing compliance with global regulations such as those from the FDA, EMA, MHRA, and ICH guidelines. How to…

How to Analyze and Present Benefit-Risk Balance in PBRERs – regulatory affairs in pharma industry How to Analyze and Present Benefit-Risk Balance in PBRERs The evaluation and presentation of the benefit-risk balance in Periodic Benefit-Risk Evaluation Reports (PBRERs) is a key component of regulatory affairs in the pharmaceutical industry. This process involves continuous assessment of medication safety and efficacy throughout the product lifecycle. In this comprehensive guide, we will delve into the detailed steps necessary to effectively analyze and present the benefit-risk balance in PBRERs, aligning with international regulatory standards. How to Structure a PBRER for Effective Benefit-Risk Analysis Structuring…

Case Narratives and Line Listings in PSUR: Regulatory Insights – pharmaceutical industry regulatory affairs Case Narratives and Line Listings in PSUR: Regulatory Insights Periodic Safety Update Reports (PSURs) are essential components of pharmacovigilance that ensure the continuous monitoring of a drug’s safety and efficacy post-approval. This article delves into the meticulous nature and regulatory expectations surrounding case narratives and line listings in PSURs. By adhering to the guidelines set forth by regulatory bodies such as the FDA, EMA, MHRA, and ICH, pharmaceutical industry professionals can ensure compliance and maintain robust drug safety profiles. How to Understand the Importance of Case…

Signal Evaluation in the Context of Periodic Safety Reports – regulatory affairs in pharma industry Signal Evaluation in the Context of Periodic Safety Reports Signal evaluation is a critical component in the preparation of Periodic Safety Update Reports (PSURs) in the pharmaceutical industry. It integrates the safety data collected during various phases of drug development and post-marketing and plays a vital role in ensuring the ongoing assessment of a product’s benefit-risk profile. This article aims to provide regulatory affairs professionals in the pharma industry with detailed guidance on conducting signal evaluation, especially as it pertains to PSURs. How to Conduct…